Myelodysplastic Syndromes (MDS)
Also known as: Myelodysplastic Syndromes(MDS) / Myelodysplastic Syndrome (MDS) / Myelodysplastic Syndrome(MDS) / Myelodysplastic Syndromes / Myelodysplastic disease / Myeloid dysplasia / Preleukaemia / [X]Myelodysplastic syndrome, unspecified (disorder) / Myelodysplasia NOS / (Myelodysplastic syndrome, unspecified) or (myelodysplasia) / (Neoplasm of uncert behav of other lymphat and haematopoietic tissue) or (neoplasm of uncert behav of blood) or (idiopathic thrombocythaemia) or (megakaryocytic myelosclerosis) or (myelodysplasia) / Preleukemia / Myelodysplasia / Myelodysplastic syndrome NOS / Refractory anemia with excess blasts (disorder) / Subacute myeloid leukemia (disorder) / Myelodysplastic syndrome / Myelodysplastic syndrome (morphology) / Myelodysplastic syndrome (disorder) / Myelodysplastic syndrome (morphologic abnormality)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB15694 | Cedazuridine | A cytidine deaminase inhibitor coadministered with the hypomethylating agent decitabine for the treatment of variable forms of myelodysplastic syndrome (MDS). |
| DB01262 | Decitabine | A chemotherapeutic pyrimidine nucleoside analogue used for the treatment of myelodysplastic syndromes (MDS) by inducing DNA hypomethylation and corresponding alterations in gene expression. |
| DB00619 | Imatinib | A tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors. |